Acute myeloid leukemia patients face limited treatment options when single-drug therapies fail, particularly those with specific genetic mutations that drive aggressive disease progression. This challenge has prompted researchers to explore combination approaches that could overcome resistance mechanisms while reducing the doses needed for effectiveness.
Laboratory studies reveal that combining ziftomenib, which targets the menin protein, with selinexor, an XPO1 inhibitor, produces synergistic killing effects against leukemia cells carrying KMT2A rearrangements or NPM1 mutations. The dual treatment suppressed colony formation in patient-derived stem cells while sparing healthy bone marrow cells. Molecular analysis showed the combination downregulated key oncogenes HOXA9 and MEIS1 while promoting cellular differentiation markers like CD11b. Mouse studies demonstrated improved survival across multiple leukemia models, including patient-derived samples, even when using reduced drug concentrations.
This work illuminates a previously unknown mechanism whereby XPO1 stabilizes menin's chromatin binding and its interactions with the KMT2A methyltransferase complex. By simultaneously disrupting menin function and destabilizing these protein interactions, the combination creates a more complete blockade of oncogenic transcriptional programs than either drug alone. While promising, these remain early preclinical findings requiring validation in human clinical trials. The approach represents incremental progress in combination therapy development rather than a paradigm shift, though the mechanistic insights about XPO1's role in chromatin regulation could inform broader therapeutic strategies. Success in clinical translation would particularly benefit the roughly 10-15% of AML patients harboring these specific mutations, who currently have few targeted options beyond intensive chemotherapy.